老年2型糖尿病神经病变合并冠心病患者治疗体会
|
摘要
目的探究前列地尔联合血塞通弥可保治疗老年2型糖尿病神经病变合并冠心病的疗效和安全性。方法方便选取该院2015年1月—2016年12月期间所收治的60例老年2型糖尿病神经病变合并冠心病患者,按照随机数表法分为观察组(n=30)和对照组(n=30),常规降血糖、降血压药物治疗和饮食控制基础上,对照组患者采用血塞通联合弥可保静脉给药治疗,观察组患者采用前列地尔联合血塞通弥可保静脉给药治疗,比较两组患者疗效、正中神经和腓总神经的运动传导速度(MCV)与感觉传导速度(SCV)及不良反应发生情况。结果观察组疗效总有效率(86.67%)与对照组(60.00%)比较差异有统计学意义(χ2=5.454 5,P=0.019 5);观察组治疗后正中神经、腓总神经MCV和正中神经、腓总神经SCV显著高于对照组[(47.88±4.35)m/s vs(42.21±3.77)m/s;(45.37±3.94)m/s vs(40.54±3.22)m/s;(48.65±5.34)m/s vs(41.28±4.17)m/s;(46.33±3.74)m/s vs(39.55±4.34)m/s],差异有统计学意义(t=5.395 1,P=0.000 0;t=5.199 1,P=0.000 0;t=5.958 0,P=0.000 0;t=6.481 9,P=0.000 0);两组患者不良反应发生率比较(6.67%vs 10.00%),差异无统计学意义(χ2=0.218 2,P=0.640 4)。结论前列地尔联合血塞通弥可保治疗老年2型糖尿病神经病变合并冠心病是一种安全有效的临床治疗方式,能有效缓解患者神经损伤,提高生活质量,具有较高临床应用价值。
Objective To study the curative effect and safety of alprostadil and xuesaitong in treatment of type 2 diabetes neuropathy and coronary heart disease. Methods 60 cases of senile patients with type 2 diabetes neuropathy and coronary heart disease admitted and treated in our hospital from January 2015 to December 2016 were convenient selected and randomly divided into two groups with 30 cases in each, both groups adopted the routine hypoglycemic drugs and hypotensive drugs and dieting control, the control group adopted the intravenous injection of xuesaitong and mecobalamin, while the observation group adopted the intravenous injection of alprostadil and mecobalamin, and the curative effect, MCV and SCV of median nerve and nerve peroneus communis and occurrence of adverse reactions were compared between the two groups.Results The difference in the total effective rate between the observation group and the control group was obvious(86.67%vs 60.00%),(χ2=5.454 5, P=0.019 5), after treatment, the MCV and SCV of median nerve and nerve peroneus communis in the observation group were obviously higher than those in the control group [(47.88±4.35)m/s vs(42.21±3.77)m/s;(45.37±3.94)m/s vs(40.54±3.22)m/s;(48.65±5.34)m/s vs(41.28±4.17)m/s;(46.33±3.74)m/s vs(39.55±4.34)m/s], and the differences were statistically significant(t=5.395 1,P=0.000 0; t=5.199 1,P=0.000 0; t=5.958 0, P=0.000 0;t=6.481 9,P=0.000 0),and the difference in the incidence rate of adverse reactions between the two groups was not statistically significant(6.67%vs 10.00%)(χ2=0.218 2,P=0.640 4). Conclusion The alprostadil and mecobalamin in treatment of type 2 diabetes neuropathy and coronary heart disease is a safe and effective clinical treatment method, which can effectively relieve the nerve injury and improve the quality of life, and it is of higher clinical application value.
Objective To study the curative effect and safety of alprostadil and xuesaitong in treatment of type 2 diabetes neuropathy and coronary heart disease. Methods 60 cases of senile patients with type 2 diabetes neuropathy and coronary heart disease admitted and treated in our hospital from January 2015 to December 2016 were convenient selected and randomly divided into two groups with 30 cases in each, both groups adopted the routine hypoglycemic drugs and hypotensive drugs and dieting control, the control group adopted the intravenous injection of xuesaitong and mecobalamin, while the observation group adopted the intravenous injection of alprostadil and mecobalamin, and the curative effect, MCV and SCV of median nerve and nerve peroneus communis and occurrence of adverse reactions were compared between the two groups.Results The difference in the total effective rate between the observation group and the control group was obvious(86.67%vs 60.00%),(χ2=5.454 5, P=0.019 5), after treatment, the MCV and SCV of median nerve and nerve peroneus communis in the observation group were obviously higher than those in the control group [(47.88±4.35)m/s vs(42.21±3.77)m/s;(45.37±3.94)m/s vs(40.54±3.22)m/s;(48.65±5.34)m/s vs(41.28±4.17)m/s;(46.33±3.74)m/s vs(39.55±4.34)m/s], and the differences were statistically significant(t=5.395 1,P=0.000 0; t=5.199 1,P=0.000 0; t=5.958 0, P=0.000 0;t=6.481 9,P=0.000 0),and the difference in the incidence rate of adverse reactions between the two groups was not statistically significant(6.67%vs 10.00%)(χ2=0.218 2,P=0.640 4). Conclusion The alprostadil and mecobalamin in treatment of type 2 diabetes neuropathy and coronary heart disease is a safe and effective clinical treatment method, which can effectively relieve the nerve injury and improve the quality of life, and it is of higher clinical application value.
引文
[1]成殷勤,胡可军.气压按摩干预联合前列地尔治疗腺苷钴胺对老年2型糖尿病周围神经病变疗效[J].医学临床研究,2016,33(12):2428-2432.
[2]梁文霞,刘海燕.α-硫辛酸联合前列地尔治疗2型糖尿病周围神经病变的临床观察[J].中国心血管病研究,2015,13(3):264-266.
[3]张松涛,鲁宏伟.老年2型糖尿病合并冠心病患者的心率变异性研究[J].海南医学,2014,25(3):326-328.
[4]唐瑛,李劲松.六味地黄丸加减联合二甲双胍辨治阴虚内热证2型糖尿病的临床研究[J].湖南师范大学学报:医学版,2015(4):28-31.
[5]高四红,郑桃林,何伟,等.依帕司他联合前列地尔治疗2型糖尿病周围神经病变的疗效[J].医学临床研究,2014,31(8):1569-1571.
[6]潘静,陈辉,郑永克.老年糖尿病周围神经病变患者应用α-硫辛酸联合甲钴胺与前列地尔治疗的疗效分析[J].中国医师杂志,2014,16(9):1232-1234.
[7]赵勤,杨晓菁,胡锐,等.血塞通注射液治疗冠心病临床疗效和安全性的系统评价[J].中成药,2014,36(12):2486-2490.
[8]刘雪辉,谢淑玲,伍文彬,等.加味黄芪桂枝五物汤治疗老年2型糖尿病周围神经病变疗效观察[J].山东医药,2015,55(34):60-61.
[2]梁文霞,刘海燕.α-硫辛酸联合前列地尔治疗2型糖尿病周围神经病变的临床观察[J].中国心血管病研究,2015,13(3):264-266.
[3]张松涛,鲁宏伟.老年2型糖尿病合并冠心病患者的心率变异性研究[J].海南医学,2014,25(3):326-328.
[4]唐瑛,李劲松.六味地黄丸加减联合二甲双胍辨治阴虚内热证2型糖尿病的临床研究[J].湖南师范大学学报:医学版,2015(4):28-31.
[5]高四红,郑桃林,何伟,等.依帕司他联合前列地尔治疗2型糖尿病周围神经病变的疗效[J].医学临床研究,2014,31(8):1569-1571.
[6]潘静,陈辉,郑永克.老年糖尿病周围神经病变患者应用α-硫辛酸联合甲钴胺与前列地尔治疗的疗效分析[J].中国医师杂志,2014,16(9):1232-1234.
[7]赵勤,杨晓菁,胡锐,等.血塞通注射液治疗冠心病临床疗效和安全性的系统评价[J].中成药,2014,36(12):2486-2490.
[8]刘雪辉,谢淑玲,伍文彬,等.加味黄芪桂枝五物汤治疗老年2型糖尿病周围神经病变疗效观察[J].山东医药,2015,55(34):60-61.